Industry News
Pharmaceutical Industry News
A Merck spokesperson attributed…
A Merck spokesperson attributed the layoffs to "the next phase of personnel impacts related to its multiyear optimization," which was unveiled last July.
A phase 3 study of Gilead’s…
A phase 3 study of Gilead’s Livdelzi has met its primary endpoint, showing that after 52 weeks it can normalize a key marker of disease progression for those with the liver disorder primary biliary cholangitis.
French drugmaker Sanofi is…
French drugmaker Sanofi is launching an AI agent to support its field reps as life sciences companies continue to ramp up their use of next-generation technology across their businesses.
As governments and health…
As governments and health authorities rush to meet the moment of a worsening Ebola outbreak in central Africa, Merck & Co. is considering dusting off its antiviral molnupiravir, which saw use as a treatment for
Cingulate will need to take a…
Cingulate will need to take a detour to win its first FDA approval, as the agency has rejected its lead candidate over manufacturing concerns.
Eisai has partnered with…
Eisai has partnered with CaringKind to expand its nutrition support initiative to cover Alzheimer's disease and related dementias.
As Ebola Spreads, Scientists Race to Find Vaccines and Treatments
The Bundibugyo virus, a little known type, previously had caused just two small outbreaks. Now it’s at the center of a rapidly widening epidemic in Africa.
Recognizing the gap in male birth…
Recognizing the gap in male birth control, Charlottesville, Virginia’s Contraline is stepping up to the plate, developing what it believes could be a first-in-class topical candidate that has now garnered enthusiasm from a host of
After a prior misfire in…
After a prior misfire in demonstrating its protease inhibitor ensitrelvir’s potential as a COVID-19 treatment for U.S. patients, Shionogi has secured an FDA green light for the medicine in the prevention setting.
HER2 combination strategies are…
HER2 combination strategies are evolving. Hear how biology and next-generation antibodies are redefining treatment.
ViiV Healthcare is teaming up with…
ViiV Healthcare is teaming up with TV personality, HIV and LGBTQ advocate Michelle Visage to help broaden awareness about new, longer-acting medicines that can significantly reduce the risk of HIV exposure.
For Meghan O’Hora, pharma…
For Meghan O’Hora, pharma marketing isn’t about patients. It’s about people and making real connections that help them see beyond their diagnosis toward a healthier future.
The company’s Emerald-3 study…
The company's Emerald-3 study showed a 30% reduction in the risk of disease progression or death among embolization-eligible liver cancer patients who used an Imfinzi and Imjudo regimen.
Merck & Co.’s extensive…
Merck & Co.’s extensive clinical development scheme for its TROP2 antibody-drug conjugate sac-TMT already includes 17 global phase 3 trials. But there’s one important missing piece.
Although the first-in-class…
Although the first-in-class PD-1xVEGF bispecific didn’t disappoint on its overall survival headline message, detailed results from ivonescimab’s chemo-combo readout in first-line lung cancer are being picked apart by a critical pair of eyes.
In its 2,000-patient Proteus…
In its 2,000-patient Proteus study, J&J tested Erleada's benefits when given to certain patients with prostate cancer before and after surgery.
China’s Rise in Drug Development Looms Over U.S.
Clinical trials in China are getting attention at an international oncology gathering in Chicago. China’s surging biotechnology industry is fueling alarm that U.S. dominance in the field is waning.
After winning a broader FDA label…
After winning a broader FDA label in metastatic castration-resistant prostate cancer, Pfizer’s combination of Talzenna and Xtandi is claiming a phase 3 win that positions it for a wider castration-sensitive patient population compared with J&J’s
In Lilly’s Libretto-432 ASCO…
In Lilly's Libretto-432 ASCO readout, Retevmo showed an 83% reduction in disease progression or death when used as an adjuvant therapy in patients with early-stage RET fusion-positive lung cancer.
Seeking a share of the first-line…
Seeking a share of the first-line diffuse B-cell lymphoma market, Incyte believes Monjuvi’s positive phase 3 results across patient subgroups will give it an edge over the standard R-CHOP regimen and Roche’s Polivy—that’s at least